Copy to clipboard 
ORTHOWORLD estimates Smith & Nephew 1Q17 orthopaedic revenue of US $826.9MM, +3.0% from 1Q16.
ORTHOWORLD estimates 1Q17 segment sales and growth on an as-reported basis, as follows.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $417.0 | $404.5 | $12.4 | 3.1% |
| Hip | $152.0 | $153.0 | -$1.0 | -0.7% |
| Knee | $251.9 | $239.0 | $12.9 | 5.4% |
| Extremities | $13.1 | $12.5 | $0.5 | 4.3% |
| Trauma | $106.9 | $101.5 | $5.5 | 5.4% |
| Arthroscopy/Soft Tissue | $303.0 | $297.0 | $6.0 | 2.0% |
| Total | $826.9 | $803.0 | $23.9 | 3.0% |
1Q17 performance highlights:
- Joint Recon driven by continued high demand for JOURNEY II total knee; investments in REDAPT revision hip and POLARSTEM cementless stem are expected to increasingly contribute to growth throughout the year
- Full market launch of JOURNEY II, LEGION and GENESIS II total knees slated for 2Q17
- NAVIO for total knee well-received at AAOS preview; have more indications under development
- “NAVIO offers advantages to our customers. It is very portable and cost effective and therefore, highly attractive both in the hospital and the ASC. It does not require a CT scan, therefore saving time and cost.”—Olivier Bohuon, Chief Executive Officer
- JOURNEY II XR Bi-cruciate Retaining Knee receiving excellent feedback in limited launch
- AR/ST supported by demand for shoulder repair and newer products (e.g. ULTRABUTTON), countered by continued softness/competitive pressure in mechanical resection; expecting increase in contribution of LENS visualization and WEREWOLF COBLATION systems throughout 2017
- Trauma revenue supported by TRIGEN INTERTAN hip fracture system, supported by annualization of reduced tender activity in Gulf states
Sources: Smith & Nephew plc; ORTHOWORLD estimates
An ORTHOWORLD Observation
Our 2016 estimates place Smith & Nephew at #4 in overall orthopaedic market share; its full-year ortho revenue of $3.2BB was just over half that of #3 player, Stryker, and $320MM more than #5 player, Medtronic.
Smith & Nephew also holds the #4 spot in Joint Reconstruction and Trauma, and is #2 for Arthroscopy/Soft Tissue Repair, where it trailed Arthrex by about $320MM in 2016.
ORTHOWORLD estimates Smith & Nephew 1Q17 orthopaedic revenue of US $826.9MM, +3.0% from 1Q16.
ORTHOWORLD estimates 1Q17 segment sales and growth on an as-reported basis, as follows.
Q17
Q16
$ Change
% Change
Joint Reconstruction...
ORTHOWORLD estimates Smith & Nephew 1Q17 orthopaedic revenue of US $826.9MM, +3.0% from 1Q16.
ORTHOWORLD estimates 1Q17 segment sales and growth on an as-reported basis, as follows.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $417.0 | $404.5 | $12.4 | 3.1% |
| Hip | $152.0 | $153.0 | -$1.0 | -0.7% |
| Knee | $251.9 | $239.0 | $12.9 | 5.4% |
| Extremities | $13.1 | $12.5 | $0.5 | 4.3% |
| Trauma | $106.9 | $101.5 | $5.5 | 5.4% |
| Arthroscopy/Soft Tissue | $303.0 | $297.0 | $6.0 | 2.0% |
| Total | $826.9 | $803.0 | $23.9 | 3.0% |
1Q17 performance highlights:
- Joint Recon driven by continued high demand for JOURNEY II total knee; investments in REDAPT revision hip and POLARSTEM cementless stem are expected to increasingly contribute to growth throughout the year
- Full market launch of JOURNEY II, LEGION and GENESIS II total knees slated for 2Q17
- NAVIO for total knee well-received at AAOS preview; have more indications under development
- “NAVIO offers advantages to our customers. It is very portable and cost effective and therefore, highly attractive both in the hospital and the ASC. It does not require a CT scan, therefore saving time and cost.”—Olivier Bohuon, Chief Executive Officer
- JOURNEY II XR Bi-cruciate Retaining Knee receiving excellent feedback in limited launch
- AR/ST supported by demand for shoulder repair and newer products (e.g. ULTRABUTTON), countered by continued softness/competitive pressure in mechanical resection; expecting increase in contribution of LENS visualization and WEREWOLF COBLATION systems throughout 2017
- Trauma revenue supported by TRIGEN INTERTAN hip fracture system, supported by annualization of reduced tender activity in Gulf states
Sources: Smith & Nephew plc; ORTHOWORLD estimates
An ORTHOWORLD Observation
Our 2016 estimates place Smith & Nephew at #4 in overall orthopaedic market share; its full-year ortho revenue of $3.2BB was just over half that of #3 player, Stryker, and $320MM more than #5 player, Medtronic.
Smith & Nephew also holds the #4 spot in Joint Reconstruction and Trauma, and is #2 for Arthroscopy/Soft Tissue Repair, where it trailed Arthrex by about $320MM in 2016.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
